Mindfulness Intervention for Improving Nutrition in the Digital Kitchen Among Stage I-III Breast Cancer Survivors, MIND Trial
NCT06643455
Recruiting
This trial tests how well a remotely-delivered nutrition and culinary intervention works to improve diet quality among stage I-III breast cancer survivors. Despite the strong evidence demonstrating the benefits of healthy nutrition on improving cancer outcomes, most breast cancer survivors, do not meet the nutrition recommendations The use of technology in behavioral interventions is proving to be a cost-effective mode of delivering lifestyle education to promote behavior change. The Mindfulness... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/04/2025
Locations: Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington
Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
Register for Updates
Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma
NCT06676319
Recruiting
This is a parallel-group, Phase 2, randomized, double-blind, placebo-controlled, 2-arm study for the treatment of asthma. The purpose of this study is to assess the efficacy, safety, and tolerability of add-on therapy with SC lunsekimig compared with placebo in male and female participants (aged 18 to 80 years, inclusive) with asthma, who are not currently eligible for biologic treatments. Study details include: * The study duration will be approximately 64 weeks for participants not transiti... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
08/04/2025
Locations: The Center for Clinical Trials - Saraland- Site Number : 8400096, Saraland, Alabama +205 locations
Conditions: Asthma
Register for Updates
Anti-VEGF Gene Therapy Trial for Vestibular Schwannoma
NCT06517888
Recruiting
This trial will evaluate the safety and tolerability of a single unilateral administration of one of three dose levels of AAVAnc80-antiVEGF and will evaluate the Akouos delivery device to safely achieve the intended product performance.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/04/2025
Locations: Johns Hopkins Hospital, Baltimore, Maryland +3 locations
Conditions: Vestibular Schwannoma
Register for Updates
Combined Guanfacine and Mindfulness Meditation as an Adjunct to Buprenorphine Maintenance in Opioid Use Disorder
NCT06642181
Recruiting
The US is currently going through an opioid crisis, and while Medication Assisted Treatments such as buprenorphine (BUP) have proved highly effective at stabilizing the neurobiology underlying acute withdrawal, they have been less effective at preventing longer-term relapse and adherence. This may be due to the fact that they do not fully engage the neural processes sub-serving the emotional control of sensitized negative mood and reward sensitivity during stress- and opioid-cue provocation, res... Read More
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
08/04/2025
Locations: Rutgers School of Health Professions, Newark, New Jersey
Conditions: Mindfulness, Guanfacine, Opioid Use Disorder
Register for Updates
Improving Congenital Heart Disease Care
NCT06581484
Recruiting
The theory-informed digital health intervention, called as "Empower My Congenital Health (EmpowerMyCH)" aims to activate and engage ACHD patients in building confidence toward navigating the adult healthcare system. This tool is built after incorporating the theories of behavior change, gathering inputs from target patients in all stages of its design and implementation. The key features of the tool include a digital medical passport, updated congenital information, community support, and patien... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/04/2025
Locations: University of California, San Francisco, San Francisco, California
Conditions: Congenital Heart Disease, Behavior, Health, Quality of Life, Empowerment, Patient, Activation, Patient
Register for Updates
Open-Label Extension of EryDex Study IEDAT-04-2022
NCT06664853
Recruiting
This is an international, multi-center, prospective, open-label, non-comparative study to provide EryDex treatment to ataxia telangiectasia (A-T) patients who complete the IEDAT-04-2022 trial on the neurological effects of EryDex on subjects with ataxia telangiectasia (NEAT trial).
Gender:
ALL
Ages:
6 years and above
Trial Updated:
08/04/2025
Locations: University of California Los Angeles (UCLA), Ataxia Center and HD Center of excellence, Los Angeles, California +20 locations
Conditions: Ataxia Telangiectasia
Register for Updates
Long-term Safety and Efficacy Evaluation of Lunsekimig (SAR443765) in Adult Participants With Moderatetosevere Asthma.
NCT06609239
Recruiting
This is a phase 2, open-label extension study to evaluate the long-term safety and efficacy of lunsekimig in adult participants with moderate-to-severe asthma who have previously completed the parent study. After completion of the parent study, eligible participants will be offered the opportunity to participate in the long-term extension (LTE) study with lunsekimig. The study duration will be up to 100 weeks with a treatment duration being up to 96 weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/04/2025
Locations: Allianz Research Institute- Site Number : 8400026, Aurora, Colorado +67 locations
Conditions: Asthma
Register for Updates
Quantification of Phosphorylated Alpha-synuclein in Cutaneous Biopsies as a Prospective Biomarker in Parkinson's Disease
NCT06621602
Recruiting
This study aims to assess the levels of phosphorylated alpha-synuclein (P-SYN) in patients with Parkinson's disease and REM Behavior Disorder using a minimally invasive skin punch biopsy. It seeks to understand the natural progression of P-SYN deposition over time to explore the potential of P-SYN quantification as a biomarker for disease progression.
Gender:
ALL
Ages:
Between 50 years and 100 years
Trial Updated:
08/04/2025
Locations: CND Life Sciences, Scottsdale, Arizona +13 locations
Conditions: REM Behavior Disorder, Parkinson Disease
Register for Updates
Transcranial Direct Current Stimulation for Treatment of Acute Ischemic Stroke
NCT06440707
Recruiting
Many patients with acute ischemic stroke are ineligible for currently available standard treatments (clot-busting medication, also known as intravenous thrombolytic or mechanical removal of a clot), and many are non-responders, resulting in a low rate of excellent outcomes, which necessitates the development of novel therapies. In this study, investigators are testing a new treatment in which a weak electrical current will be applied via scalp electrodes to increase collateral blood flow to the... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/04/2025
Locations: University of California- Los Angeles (UCLA), Los Angeles, California +2 locations
Conditions: Acute Ischemic Stroke
Register for Updates
Using Consumer-grade Wearable Devices for Fall Risk Evaluation and Alerts
NCT06508892
Recruiting
Creation and use of a smartphone application for older adults to assess the participants' risk of fall. Phase 1: Compare the accuracy and validity of accelerometer and gyroscopic data from a smartphone and gold-standard, wearable sensors gathered during balance and gait activities. Phase 2: Develop a model that integrates wearable sensor data and individual characteristics, such as age, medical conditions, exercises, previous falls, fear of falls, along with gait and balance outcome measurements... Read More
Gender:
ALL
Ages:
65 years and above
Trial Updated:
08/04/2025
Locations: University of Michigan-Flint, Flint, Michigan
Conditions: Mass Screening
Register for Updates
A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors
NCT06685068
Recruiting
The purpose of this trial is to evaluate the safety, tolerability, pharmacokinetics (PK), anti-tumor activity and immunogenic potential of GEN1286 in participants with advanced solid tumors. This trial consists of 2 parts: * Part A: Dose escalation and dose level expansion * Part B: Tumor-specific expansion with dose optimization
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/04/2025
Locations: START Midwest, Grand Rapids, Michigan +2 locations
Conditions: Advanced Solid Tumor
Register for Updates
Wearable Evaluation of Ambulatory Readings for Blood Pressure
NCT06610448
Recruiting
The purpose of this project is to compare the performance and validity of novel wearable technologies that measure blood pressure (BP) and physical activity with a Spacelabs Ambulatory Blood Pressure Monitoring (ABPM) device.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
08/04/2025
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts
Conditions: Normal Blood Pressure, Controlled Hypertension, Uncontrolled Hypertension
Register for Updates